Shire collaboration (2009) - lead candidates against up to five targets

  • Santaris Pharma A/S responsible for design and selection of lead candidates
  • Shire responsible for pharmacology and further development
  • Upfront/milestones in excess of $380m, FTE funding; undisclosed royalties
  • Worldwide commercial rights partnered

Pfizer collaboration (2008) - lead candidates against up to 10 targets

  • Santaris Pharma A/S responsible for design and delivery of lead candidates
  • Pfizer responsible for pharmacology and further development
  • Upfront/milestones in excess of $800m; FTE funding; and double-digit royalties
  • Worldwide commercial rights partnered

GSK collaboration (2007) - GSK options to drug candidates from up to four viral disease programs

  • Santaris Pharma A/S responsible for development to completion of phase 2a trials
  • Upfront/milestones in excess of $700m; double-digit royalties
  • Worldwide commercial rights partnered

Enzon collaboration (2006) - lead candidates against eight cancer targets

  • Two clinical stage programs; Development of lead candidates against six additional cancer targets
  • All six drug candidates designed, synthesized and selected within 24 months of signing agreement
  • Upfront / milestones in excess of $200m; high single-digit royalties
  • Santaris Pharma A/S retains commercial rights in Europe; milestones and royalties worldwide
sylvie_head

"With this novel platform technology Shire has the potential to move into a wider range of genetic orphan diseases. We will look to develop treatments for people with a variety of rare life-altering and life-threatening conditions that to date, could not be effectively addressed by enzyme replacement therapy."

-Dr. Sylvie Grégoire, President of Shire Human Genetic Therapies

sylvie_head

"We are very pleased with our choice to collaborate with Santaris Pharma and utilize its LNA Drug Platform to successfully develop RNA-targeted medicines. Santaris Pharma designed, synthesized and in collaboration with Enzon’s scientists selected all six drug candidates - a major accomplishment in drug discovery. We look forward to further advancing our pipeline of LNA-based drugs in the coming years."

-Dr. Ivan Horak, President of Research, Development and Chief Scientific Officer of Enzon Pharmaceuticals